NBC/NY Link: Goldman Sachs Says National Mask Mandate Could Slash Infections, Save Economy From 5% Hit
Briefly noted: G Bommelear et al. Clin Gastroenterol Hepatol; 2020; 18: 1553-60. Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn’s Disease After Surgery in a Randomized Controlled Trial
- Double-blind randomized controlled trial at 8 referral centers in France, from October 2014 through January 2018, with 62 consecutive patients with CD undergoing bowel resection.
- Patients received azathioprine (2.5 mg/kg) and were randomly assigned to groups given oral curcumin (3 g/day; n = 31) or an identical placebo (n = 31) for 6 months, and were then evaluated by colonoscopy.
- The primary endpoint: postoperative recurrence of CD in each group (Rutgeerts’ index score ≥i2) at month 6
- Postoperative recurrence at 6 months: (Rutgeerts’ index score ≥i2): 58% receiving curcumin vs 68% receiving placebo (P = .60).
- Severe recurrence: 55% receiving Curcumin 55%vs 26% receiving placebo –had a severe recurrence of CD (Rutgeerts’ index score ≥i3) (P = .034).
- Clinical recurrence of CD (CD activity index score >150) at 6 months: 30% with curcumin compared with 45% receiving placebo (P = .80)
My take: Curcumin was ineffective in preventing recurrent post-operative Crohn’s disease
Related blog posts:
- Spice It Up! Curcumin for Ulcerative Colitis
- Expert Guidance on Inflammatory Bowel Disease (Part 2)
- Nutrition Week (Day 7) Connecting Epidemiology and Diet in Inflammatory Bowel Disease | gutsandgrowth
- Herbal Medicines for IBD and IBS | gutsandgrowth
- The Search for a Dietary Culprit in IBD | gutsandgrowth